Navigation Links
Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting

a targeted inhibitor of the 17-alpha hydroxylase/c17,20 lyase enzyme, which is currently being tested in Phase II clinical trials in prostate cancer; CB3304, an inhibitor of microtubule dynamics, which is currently in a Phase I trial in hematological malignancies and CB1089, an analog of vitamin D, which has been clinically tested in a number of solid tumor types.

Further information about Cougar Biotechnology can be found at www.cougarbiotechnology.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as ``anticipates,'' ``expects,'' ``plans,'' ``believes,'' ``intends,'' and similar words or phrases. These forward-looking statements include, without limitation, statements related to benefits to be derived from Cougar's drug development programs, including the potential advantages of CB7630 and its potential for use in the treatment of CRPC and in second line hormone and chemotherapy treatment settings. Such statements involve risks and uncertainties that could cause Cougar's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in clinical trials, and drug development and commercialization, including the uncertainty of whether results in testing of CB7630 will be predictive of results in later stages of development. For a discussion of these and other factors, please refer to Cougar's annual report on Form 10-KSB for the year ended December 31, 2006 as well as other subsequent filings with the Securities and Exchange
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
2. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
3. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
4. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
7. Prana Biotechnology Presents New Key Findings on PBT2
8. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:3/31/2015)... DIEGO , March 31, 2015 Neurocrine ... it has entered into an exclusive collaboration and licensing ... inhibitor, NBI-98854, in Japan and ... (TSE: 4508). Mitsubishi Tanabe intends to initially develop NBI-98854 ... associated with Huntington,s disease and tardive dyskinesia. Neurocrine retains ...
(Date:3/31/2015)... , March 31, 2015 UHC has ... the use of medical devices based on cost and ... physician preference items (PPIs). The study examined utilization of ... hospital,s supply expenses 1 —at 10 academic medical centers, ... stents, and cardiac valves. The study, ...
(Date:3/31/2015)... and ORANGEBURG, N.Y., March 31, 2015 /PRNewswire/ ...  VSCI) today announced the completion of their merger. ... and completion of the all-stock combination creates a ... Beginning on April 1, 2015, Cogentix Medical, Inc. ... CGNT. Cogentix Medical will have its U.S. headquarters ...
Breaking Medicine Technology:Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 2Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 3Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 4UHC Study: Variations in Use of Physician Preference Items Affect Patient Outcomes and Costs 2UHC Study: Variations in Use of Physician Preference Items Affect Patient Outcomes and Costs 3Uroplasty and Vision-Sciences Complete Merger 2Uroplasty and Vision-Sciences Complete Merger 3Uroplasty and Vision-Sciences Complete Merger 4
... Data,presented at the 2007 Annual Scientific Meeting of ... alli(R) (orlistat 60mg), the,only FDA- approved, over-the-counter (OTC) ... in helping them lose weight, and,not to potential ... data show that the weight loss achieved with ...
... Sanofi-aventis announced today,that the Japanese Ministry of ... for a Supplemental New Drug Application (sNDA) ... angina pectoris, non-ST elevation,myocardial infarction) for which ... Plavix(R) (clopidogrel). Approximately 100,000 patients develop ...
Cached Medicine Technology:Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects 2Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects 3Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned 2Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned 3Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned 4Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned 5
(Date:4/1/2015)... (PRWEB) April 01, 2015 Nike Golf ... Development Camps in Arizona and Florida. These programs are ... lower their score in a golf-intensive environment and to ... led by University of Arizona coaching legend, Rick LaRose, ... on the knowledge gaps as it pertains to the ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Enterprise ... 501 Global Edition, a distinguished list and report ... (MSPs). The complete 501 list is currently available ... ,     The top ranked MSPs in North America ... East and Africa ,     The top MSPs ...
(Date:3/31/2015)... Every day a new diet fad is introduced in ... in other countries, and the diagnosis of American's with ... Natural Health Centers believe that by educating not only ... the future development of obesity and many other debilitating ... at no charge in their clinics. Because yo-yo and ...
(Date:3/31/2015)... Los Angeles, CA (PRWEB) March 31, 2015 ... the robotic hair transplant technique have yielded ... manual method , when refined and perfected by a ... results. While the most advanced techniques of hair restoration ... manual techniques can still be used to add precision ...
(Date:3/31/2015)... In conjunction with the Asbestos Awareness ... Mesothelioma Applied Research Foundation (Meso Foundation) announced the ... its existing work in mesothelioma research, education, support, ... Meso Foundation’s mission, we want to eliminate harmful ... asbestos, including mesothelioma,” said the Meso Foundation’s executive ...
Breaking Medicine News(10 mins):Health News:US Sports Camps and Nike Golf Camps to Host Golf Development Camps in Arizona and Florida 2Health News:US Sports Camps and Nike Golf Camps to Host Golf Development Camps in Arizona and Florida 3Health News:Penton Technology Names Enterprise Integration to the MSPmentor 501 Global Edition 2Health News:Penton Technology Names Enterprise Integration to the MSPmentor 501 Global Edition 3Health News:Beverly Hills Hair Transplant Surgeon Now Combines Advanced Robotic Hair Transplantation and Manual Techniques for Greatest Results 2Health News:Mesothelioma Research Organization Announces New Prevention Program 2Health News:Mesothelioma Research Organization Announces New Prevention Program 3
... , , , , ... Field of Green Chemistry September 15 at UC Berkeley Campus ... Consumer concerns over hazardous chemicals in the air and water have ... chemistry. "The most troubling health effects are associated with endocrine disrupting ...
... will respond to cancer drug , TUESDAY, Sept. 8 (HealthDay ... certain aggressive cancers -- including those that attack the pancreas, ... drug. , The key appears to lie in a molecular ... issue of Nature Medicine . , Researchers at the ...
... agent lapatinib to delay tumor growth and improve the ... cancer, only benefited certain subgroups of patients. While results ... toxicity from the drug in the form of a ... and longer survival. Findings of this phase ...
... By investigating a rare and severe form of diabetes ... new molecular mechanism that regulates specialized pancreatic cells and ... which UI researchers previously linked to potentially fatal human ... this week in the Early Edition of the ...
... awarded a consortium of Chicago-based institutions, led by Rush ... a Developmental Center for AIDS Research, creating a comprehensive ... translational research in the prevention, detection and treatment of ... one of only two in the Midwest the ...
... MINNEAPOLIS/ST. PAUL (September 8, 2009)The Center for Infectious ... of Minnesota is convening an international summit on ... The summit will give business and health ... to protect employee health, critical operations and customer ...
Cached Medicine News:Health News:Inventor of Green Catalysts Offers Solutions for Cleaning Toxins and Pollutants in the Environment 2Health News:Lapatinib shows minimal effect against liver cancer 2Health News:Lapatinib shows minimal effect against liver cancer 3Health News:Team reveals molecular mechanism underlying a form of diabetes 2Health News:NIH awards major grant to Chicago-based consortium to create center for AIDS research 2Health News:NIH awards major grant to Chicago-based consortium to create center for AIDS research 3Health News:U of M convenes a summit on the H1N1 influenza pandemic and critical business preparedness 2
... Projector Chart w/ Remote/Controller. Includes ... Adults & Children. Multiple 20/20 slides. ... Programmable feature allows you to customize your ... Halogen Illumination with Long Life. Variety of ...
... The Ultimate in ... Octopus 4.3 stabilizer features ... unmatched stability in the ... 4.3 Stabilizer features the ...
... Inc., the leader in beating heart bypass, ... new Starfish NS device is the first ... patient acceptance of surgical revascularization.,The Starfish NS ... the Multi-Vessel Small Thoracotomy (MVST) procedure without ...
Part of the Octopus System which includes both the Starfish & Octopus3. The Octopus3 Tissue Stabilizer is the pioneering and market-leading suction device....
Medicine Products: